Drug
AR-12286 clinical trials
Also written AR-12286.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2009
How studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
10 studies that test it; most in 2011 (3)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 3 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 9
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 2
Aerie Pharmaceuticals (8) · Robert Ritch, MD, LLC. (1) · New York Glaucoma Research Institute (1)
Often tested with
Tested in the same studies.
Travoprost (1) · Latanoprost (1) · PG286 (1)
Studies
Open first, then newest update. How each study uses AR-12286 is read from its arms, and is right about nine times in ten.
Testing it · 10
- A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 MonthsCompletedPhase 2Aerie PharmaceuticalsNCT01699464Written as AR-12286 Ophthalmic Solution 0.7%
- A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or GlaucomaCompletedPhase 2Robert Ritch, MD, LLC.NCT01936389Written as AR-12286
- AR-12286 Fixed Dose Combination to Lower Elevated Intraocular PressureCompletedPhase 2Aerie PharmaceuticalsNCT01474135Written as 0.25% AR-12286 / 0.004% travoprost
- A Compassionate Case Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Glaucoma Patients With Uncontrolled Intraocular Pressure to Avoid Surgical InterventionStatus unknownPhase 2New York Glaucoma Research InstituteNCT02174991Written as Rho-Kinase Inhibitor (AR-12286)
- AR-12286 in Combination With LatanoprostCompletedPhase 2Aerie PharmaceuticalsNCT01302249Written as AR-12286 Ophthalmic Solution 0.5%
- Study of AR-12286 Versus Latanoprost in Patients With Elevated Intraocular PressureCompletedPhase 2Aerie PharmaceuticalsNCT01060579Written as AR-12286 0.5% ophthalmic solution
- A Study of AR-12286 in Patient With Elevated Intraocular Pressure (IOP)CompletedPhase 2Aerie PharmaceuticalsNCT00902200Written as AR-12286
- 24-hour Efficacy of AR-12286CompletedPhase 2Aerie PharmaceuticalsNCT01330979Written as AR-12286 0.5% Ophthalmic Solution
- A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 DaysCompletedPhase 2Aerie PharmaceuticalsNCT01789736Written as AR-12286 Ophthalmic Solution 0.5%
- Formulation Comparison in Normal VolunteersCompletedPhase 1Aerie PharmaceuticalsNCT01250197Written as AR-12286